Abstract
Metabolites of a G protein-coupled receptor modulator containing 1,2,4-oxadiazole and piperazine substructures were identified in vitro in human, rat, and dog hepatocyte incubates and in vivo in rat plasma, bile, urine, and feces by using 14C-radiolabeled parent compound. Exposure coverage for the major circulating metabolites in humans at steady state and in preclinical species used in drug safety assessments was determined by using pooled plasma samples collected from a human multiple ascending dose study and a 3-month rat toxicokinetic study. Metabolites M1 and M2, which were formed by opening of the 1,2,4-oxadiazole ring, were observed as major metabolites both in vitro and in vivo across species. The carboxylic acid metabolite M2 was presumably formed through reductive N-O bond cleavage of the oxadiazole ring and subsequent hydrolysis. However, the mechanism for the formation of the unusual N-cyanoamide metabolite M1 remains uncertain. Neither M1 nor M2 had any target activity, as did parent drug P. In rat bile, rearranged Cys-piperazine and Gly-Cys-piperazine adducts, involving the formation of a five-membered heteroaromatic imidazole derivative from a six-membered piperazine ring, were observed as minor metabolites. These findings support a previously reported mechanism regarding glutathione detoxification for piperazine bioactivation products.
Footnotes
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
ABBREVIATIONS:
- Ar
- aromatic
- ABT
- 1-aminobenzotriazole
- AO
- aldehyde oxidase
- AUC
- area under the curve
- BDC
- bile duct-cannulated
- CID
- collision-induced dissociation
- DMF
- dimethylformamide
- FMO
- flavin-containing monooxygenase
- LC
- liquid chromatography
- HPLC
- high-performance liquid chromatography
- MAD
- multiple ascending dose
- MB243
- N-(1-(4-(tert-butylcarbamoyl)-4-cyclohexylpiperidin-1-yl)-3-(4-fluorophenyl)-1-oxopropan-2-yl)-4-methylpiperazine-2-carboxamide
- MeCN
- acetonitrile
- MS
- mass spectrometry
- MS/MS
- tandem mass spectrometry
- MS3
- mass spectrometry/mass spectrometry/mass spectrometry
- P450
- cytochrome P450
- SM-6586
- methyl 5-(3-((benzyl(methyl) amino)methyl)-1,2,4-oxadiazol-5-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate
- TK
- toxicokinetic
- TFA
- trifluoroacetic acid.
- Received January 16, 2012.
- Accepted March 5, 2012.
- Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|